[CAS NO. 1357920-84-3] Belizatinib
PRODUCTS SPECIFICATIONS [1357920-84-3]
DESCRIPTION [1357920-84-3]
Overview
| MDL | MFCD31382200 |
|---|---|
| Molecular Weight | 577.73 |
| Molecular Formula | C33H44FN5O3 |
| SMILES | O=C(NC1=NC2=CC=C(CN3CCC(C(C)(O)C)CC3)C=C2N1[C@H]4CC[C@@H](C(NC(C)C)=O)CC4)C5=CC=C(F)C=C5 |
1 Publications Citing Use of MCE
Summary
IC50 & Target
IC50: 0.7 nM (ALK) [1]
In Vitro
TSR-011 has antitumour activity in the clinical trials.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
TSR-011 exerts sustained potent inhibition of ALK-dependent tumour growth in mouse models [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02048488 | Tesaro, Inc. |
Solid Tumors|Lymphomas
|
October 2012 | Phase 1|Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 300 mg/mL ( 519.27 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.7309 mL | 8.6546 mL | 17.3091 mL |
| 5 mM | 0.3462 mL | 1.7309 mL | 3.4618 mL |
| 10 mM | 0.1731 mL | 0.8655 mL | 1.7309 mL |